Mylan Badly Needs Help From FDA To Escape Its Woes And Deliver These Key Drugs
Mylan NV's (MYL) woes winning federal approval for two potentially profit-driving generics shows how hard a time drugmakers have launching "biosimilars" to rival complex biologic drugs that have been fattening the bottom lines of their competitors.
On Wednesday, Aug. 9, Mylan reported second-quarter numbers that came in below analysts' estimates amid pricing pressures facing generics makers.
On Wednesday, Aug. 9, Mylan reported second-quarter numbers that came in below analysts' estimates amid pricing pressures facing generics makers.